Android app on Google Play

Exact Sciences (EXAS) a One Trick Pony But Can Still Turn Heads

October 8, 2012 10:25 AM EDT Send to a Friend
Shares of Exact Sciences (Nasdaq: EXAS) moved higher today after the company was featured in a weekend report by Barron’s. The company is developing a test that can detect colon cancers with more accuracy than screenings that are currently in use. If the test is eventually approved by the FDA, Exact Sciences could be acquired for upward of $20 per share, Barron's said.

Shares of Exact Sciences last traded at $11.92, up 2.5 percent from Friday's close.




You May Also Be Interested In


Related Categories

Insiders' Blog

Related Entities

Barron's

Add Your Comment